(Press-News.org) STANFORD, Calif. — People with a blood cancer — myelofibrosis — can benefit from a drug called ruxolitinib, according to a randomized, double-blind, placebo-controlled clinical trial that included patients and researchers from the Stanford University School of Medicine. The results of the multi-site phase-3 trial, which will be published in the March 1 issue of the New England Journal of Medicine, led the Food and Drug Administration to approve the drug in November as treatment for people with intermediate or advanced cases of the disease.
Ruxolitinib is marketed as Jakafi by Incyte Corp., which funded the trial, known as COMFORT-1. Investigators at the MD Anderson Cancer Center in Houston and the Mayo Clinic in Scottsdale, Ariz., led the study. The Stanford arm of the trial was managed by Jason Gotlib, MD, MS, associate professor of medicine. More than 300 patients at 89 clinical sites participated in the trial.
"Patients with myelofibrosis have a quality of life that is severely impaired," said Gotlib, who treats between 50 and 75 newly diagnosed people each year in his Stanford clinic. Fifteen of his patients participated in the study, making Stanford the single largest recruiting site.
Individuals with advanced forms of myelofibrosis develop worsening blood counts, spleen enlargement and other symptoms including fever, night sweats and pain in their bones and muscles. "With massive splenomegaly, patients develop abdominal discomfort, early satiety and weight loss," said Gotlib. In the study, many patients who received the drug experienced a significant reduction in spleen volume and a lessening of symptoms.
Hagop Kantarjian, MD, chair of the department of leukemia in the division of cancer medicine at MD Anderson Cancer Center, is the senior author. The first author is Srdan Verstovsek, MD, PhD, an associate professor in the same department at MD Anderson.
"Our clinical experience indicates that ruxolitinib is clearly better at relieving patients' symptoms and quality of life than anything we could offer them before," said Gotlib. A parallel phase-3 randomized trial named COMFORT-2, which was conducted in Europe, demonstrated that ruxolitinib was also superior to the best available therapy in reducing spleen size and disease-related symptoms.
Myelofibrosis belongs to a class of diseases known as myeloproliferative neoplasms, or MPNs, that affect about 150,000 people in this country. About 30,000 of these have myelofibrosis. MPNs occur when the bone marrow begins to overproduce red blood cells, platelets or white blood cells. In myelofibrosis, the abnormal proliferation of these cells leads to extensive scarring within the bone marrow, making it less effective at making blood for the body. As a result, the body moves blood production to the spleen and liver, which become enlarged as they try to compensate for the underperforming marrow. People with MPNs can develop life-threatening blood clots and bleeding, and in some cases their condition progresses to acute leukemia. Some MPNs respond well to current treatments, but myelofibrosis does not.
Although myelofibrosis typically progresses slowly, patients often exhibit an inexorable course resulting in premature death. The overall survival ranges from 11 years in low-risk patients to a little more than two years in patients with high-risk disease. Stem cell transplantation can cure some patients, but it is available to only a small proportion of patients and can carry substantial treatment-related morbidity and mortality.
Ruxolitinib is the first FDA-approved therapy for the disorder, and the first of a class of compounds called JAK2 inhibitors. This targeted therapy was developed to block the action of the JAK2 tyrosine kinase protein, which is mutated and abnormally active in 50-60 percent of myelofibrosis cases. However, for reasons that are not entirely understood, the drug works in patients regardless of whether they have the mutant protein.
In the trial, patients were randomly assigned to receive either ruxolitinib (155 patients) or a placebo (154 patients) orally twice a day. Their spleen volumes were monitored over the course of the 24-week study by magnetic resonance imaging, and patients reported their symptoms using an electronic diary. The primary endpoint in the study was a 35 percent reduction in spleen volume.
"It quickly became apparent who was getting the placebo and who was getting the drug," said Gotlib, noting that the spleen volume in people receiving the drug began to decrease within one to two weeks. All told, 41.9 percent of patients on the drug met the study endpoint of at least a 35 percent reduction in spleen volume, while only 0.7 percent of those on the placebo did so. Patients receiving placebo were allowed to crossover to active, unblinded treatment with ruxolitinib after a designated period of time.
Nearly 46 percent of patients on ruxolitinib reported an improvement of 50 percent or more in their disease-associated symptoms, versus about 5 percent of those on placebo. The drug did have some side effects, however, including anemia. And although the majority patients maintained a smaller spleen volume for at least 48 weeks while on the drug, their spleens began to enlarge again if they stopped taking the drug.
"Ruxolitinib doesn't cure the disease," said Gotlib, "but the degree of benefit is clinically meaningful and substantial, and allows many patients to re-engage in their daily activities."
Compared with placebo, ruxolitinib therapy was associated with a 50 percent reduction in mortality after nearly one year of follow-up, but Gotlib indicated that the long-term implications of these data are not clear. He believes that the FDA approval of ruxolitinib and the ongoing evaluation of other JAK inhibitors in clinical trials will continue to spur drug development for myelofibrosis and similar orphan diseases for which there is a large unmet need. Ruxolitinib is now being evaluated in clinical trials of other MPNs.
###
Gotlib received an honorarium from Incyte for serving at an advisory board meeting in 2011. He also received research funding to administer the Stanford portion of the COMFORT-1 trial.
The Stanford University School of Medicine consistently ranks among the nation's top medical schools, integrating research, medical education, patient care and community service. For more news about the school, please visit http://mednews.stanford.edu. The medical school is part of Stanford Medicine, which includes Stanford Hospital & Clinics and Lucile Packard Children's Hospital. For information about all three, please visit http://stanfordmedicine.org/about/news.html.
PRINT MEDIA CONTACT: Krista Conger at (650) 725-5371(kristac@stanford.edu)
BROADCAST MEDIA CONTACT: M.A. Malone at (650) 723-6912 (mamalone@stanford.edu)
END
Since 2008, Habitatter.com has been offering the highest quality in home decorating accessories. Now, they are adding some additional product lines, including kick plates, wall trim and picture frames.
Greg Simerlink, owner of Habitatter.com, said, "I am very excited to introduce these new product lines. We are always striving to expand our offerings, and are looking to become one-stop shopping for all your home decor needs."
To celebrate, Habitatter.com is offering 10% off their Muscle Car Accessories collection for the entire month of March. Muscle Car ...
BOSTON, MA – February 29, 2012 – TREM Rx, Inc., a biotechnology company with a proprietary technology platform for novel vaccines delivered to the skin, announced today the results of an in vivo preclinical study that shows, for the first time, that powerful cells of the immune system called TREMs (T Resident Effector Memory cells) prevalent in the skin can mediate a protective immune response that is far stronger than memory T cells that circulate in the bloodstream. The study was published in today's online edition of Nature and was led by TREM Rx scientific founder, ...
Sophia Antipolis, 1 March 2012: In a groundbreaking White Paper published today in the European Heart Journal, the European Society of Cardiology (ESC) has set out its perspective on the relationship between the healthcare industry and professional medical associations with regard to the funding and delivery of continuing medical education (CME).
Essential in helping to reduce the burden of cardiovascular disease across Europe – the ESC's over-arching mission – physicians have both a professional and ethical duty to undertake CME in order to provide the highest level ...
Blue whale vocal behavior is affected by man-made noise, even when that noise does not overlap the frequencies the whales use for communication, according to new research published Feb. 29 in the open access journal PLoS ONE. The whales were less likely to emit calls when mid-frequency sonar was present, but were more likely to do so when ship sounds were nearby, the researchers report.
The study was conducted in the Pacific Ocean off the coast of Southern California by Mariana Melcon and her colleagues from University of California San Diego. Blue whale vocalizations ...
Knowledge about animal diet can inform conservation strategy, but this information can be difficult to gather. A new DNA-based method, which analyzes genetic material from feces, could be a useful tool, and researchers have shown its utility to characterize the diet of snow leopards in Mongolia. The full results are reported Feb. 29 in the open access journal PLoS ONE.
Analysis of DNA from 81 fecal samples showed that the leopards ate mostly Siberian ibex, followed by domestic goats and wild sheep. Most of the animals eaten were wild (79 %), with a relatively low proportion ...
Millions of years after its extinction, Triceratops is inciting controversy about how to classify the ancient animals. New analysis, published Feb. 29 in the open access journal PLoS ONE, suggests that the specimens in question should be classified into two separate groups, Triceratops and Torosaurus, and are not individuals of different ages from the same genus, as others have proposed.
The researchers, led by Nicholas Longrich of Yale University, performed detailed morphological and computational analysis of 35 specimens and found evidence that Triceratops and Torosaurus ...
"We used a trick called earthshine observation to look at the Earth as if it were an exoplanet," says Michael Sterzik (ESO), lead author of the paper [1]. "The Sun shines on the Earth and this light is reflected back to the surface of the Moon. The lunar surface acts as a giant mirror and reflects the Earth's light back to us — and this is what we have observed with the VLT."
The astronomers analyse the faint earthshine light to look for indicators, such as certain combinations of gases in the Earth's atmosphere [2], that are the telltale signs of organic life. This method ...
A repression of gene activity in the brain appears to be an early event affecting people with Alzheimer's disease, researchers funded by the National Institutes of Health have found. In mouse models of Alzheimer's disease, this epigenetic blockade and its effects on memory were treatable.
"These findings provide a glimpse of the brain shutting down the ability to form new memories gene by gene in Alzheimer's disease, and offer hope that we may be able to counteract this process," said Roderick Corriveau, Ph.D., a program director at NIH's National Institute of Neurological ...
Some women considering breast augmentation worry that, after having this procedure, styles will change and they will, of a sudden, be out of fashion. It is important to remember that fashions do change. Every year there are new clothing options, often in flattering shapes and colors. What is more likely is that smaller, undefined breasts actually inhibit you form wearing the latest fashions and may completely eliminate many clothing options.
Style and fashion are not the same thing. Breast augmentation isn't about fashion, it's about style; your style to be specific. ...
In a mouse model of Alzheimer's disease, memory problems stem from an overactive enzyme that shuts off genes related to neuron communication, a new study says.
When researchers genetically blocked the enzyme, called HDAC2, they 'reawakened' some of the neurons and restored the animals' cognitive function. The results, published February 29, 2012, in the journal Nature, suggest that drugs that inhibit this particular enzyme would make good treatments for some of the most devastating effects of the incurable neurodegenerative disease.
"It's going to be very important ...
